Combination Intervention-University of California, San Francisco-HIV infection

This multi-component combination immunotherapy regimen is being developed by the University of California, San Francisco (UCSF) to induce sustained HIV remission (functional cure) in individuals living with HIV. The intervention follows a multi-stage 'prime-boost-kill' strategy designed to enhance HIV-specific T cell responses and neutralize the viral reservoir. The regimen consists of: (1) therapeutic vaccination with a DNA vaccine targeting conserved elements (CE) of the HIV Gag protein (p24CE) adjuvanted with Interleukin-12 (IL-12); (2) a viral vector boost using Modified Vaccinia Ankara (MVA/HIV62B); (3) administration of two broadly neutralizing antibodies (bNAbs), 10-1074 (targeting the V3 loop) and VRC07-523LS (targeting the CD4 binding site); and (4) lefitolimod, a Toll-like receptor 9 (TLR9) agonist acting as an innate immune stimulator. This combinatorial approach aims to achieve post-intervention control of HIV after the analytical interruption of antiretroviral therapy (ART).

Other names

UCSF HIV Remission Combination Therapyp24CE/IL-12 + MVA62B + 10-1074 + VRC07-523LS + lefitolimod